Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 23,963 shares at $46.01 ($1.1M) on 2025-10-07, disclosed to the SEC on 2025-10-09.
Scheduled sale ($1.1M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.01 | 11,463 | $527K | 47.8% |
| 2 | $46.01 | 11,463 | $527K | 47.8% |
| 3 | $46.82 | 1,037 | $49K | 4.4% |
| Total | $46.05 avg | 23,963 | $1.1M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $124K | — | Filing → |